Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06971991 · ClinicalTrials.gov registry record · NA
qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver
A NA study of Transarterial Embolism and Transarterial Chemoembolization, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06971991: Recruiting NA study of Transarterial Embolism and Transarterial Chemoembolization, sponsored by University of Wisconsin, Madison.
NCT06971991 is a NA study of Transarterial Embolism and Transarterial Chemoembolization that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06971991, a NA study of Transarterial Embolism and Transarterial Chemoembolization, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to evaluate a new technique, quantitative digital subtraction angiography (qDSA), to measure blood flow during liver embolization procedures. Liver transarterial embolization is a way of treating liver tumors by blocking blood flow to it. The qDSA technique could help doctors ensure the blood flow to the tumor is decreased by the right amount by calculating blood flow before, during, and after the procedure. Up to 20 participants will be enrolled for 1 study visit and data collection for up to 6 months.
Conditions Studied
Interventions
- DEVICE qDSA Blood Flow Measurement
Study Locations (1)
Wisconsin
- UW Hospital and Clinics - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-03-13 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT06971991 shows while recruiting
NCT06971991 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Transarterial Embolism appearing as the primary indexed condition, and to 1 intervention - of which qDSA Blood Flow Measurement is the first listed.
NCT06971991 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06971991 about?
NCT06971991 is a clinical study titled "qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver". The purpose of this research is to evaluate a new technique, quantitative digital subtraction angiography (qDSA), to measure blood flow during liver embolization procedures. Liver transarterial embolization is a way of treating liver tumors by blocking blood flow to it. The qDSA technique could help...
What is the current status of trial NCT06971991?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-03-13. Estimated completion is 2026-12.
What conditions does trial NCT06971991 study?
This clinical trial studies the following conditions: Transarterial Embolism, Transarterial Chemoembolization.
What interventions are being tested in trial NCT06971991?
The interventions under investigation include: qDSA Blood Flow Measurement (DEVICE).
Who is sponsoring clinical trial NCT06971991?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06971991 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06971991's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI